Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis...

[cafead]

via Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer.

The FDA has approved Pfizer’s etrasimod under the brand name Velsipity as an oral, once-daily treatment for adults with moderate to severe active ulcerative colitis, the company said Friday.

article source

 

[anonymous]

As I read thru this exchange I see something interesting. I see some reports of potential misconduct and a request of proof. I don't see a denial yet. Why would there not be a denial and just prove it repeated. I mean if I was confident I wouldn't just ask for proof I would give proof that it's not true! Maybe just me but flabbergasted!